author_facet Slovak, Marilyn L.
Enriquez, Elmon L.
Bedell, Victoria
Kim, Young
Huang, Qin
Smith, David
Stein, Anthony
Forman, Stephen J.
Slovak, Marilyn L.
Enriquez, Elmon L.
Bedell, Victoria
Kim, Young
Huang, Qin
Smith, David
Stein, Anthony
Forman, Stephen J.
author Slovak, Marilyn L.
Enriquez, Elmon L.
Bedell, Victoria
Kim, Young
Huang, Qin
Smith, David
Stein, Anthony
Forman, Stephen J.
spellingShingle Slovak, Marilyn L.
Enriquez, Elmon L.
Bedell, Victoria
Kim, Young
Huang, Qin
Smith, David
Stein, Anthony
Forman, Stephen J.
Blood
Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
Cell Biology
Hematology
Immunology
Biochemistry
author_sort slovak, marilyn l.
spelling Slovak, Marilyn L. Enriquez, Elmon L. Bedell, Victoria Kim, Young Huang, Qin Smith, David Stein, Anthony Forman, Stephen J. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v110.11.3500.3500 <jats:title>Abstract</jats:title> <jats:p>A number of prognostically important genetic subtypes of acute lymphoblastic leukemia (ALL) has been identified. Most notably, the presence of t(9;22)/BCR-ABL1 or 11q23/MLL rearrangements in B-cell ALL is a poor prognostic indicator and patients with these subtypes of ALL are candidates for allogeneic stem cell transplantation. Consequently, early detection of minimal residual disease (MRD) is critical for appropriate diagnostic and therapeutic decisions. Current methods for MRD measurements are based on morphologic examinations, flow cytometry, quantitative reverse-transcription polymerase chain reaction (Q-RT-PCR) and cytogenetics/fluorescence in situ hybridization (FISH). While high abnormality rates ease disease detection through standard morphologic and cytogenetic analyses, the presence of cytogenetically-aberrant lymphoblasts at low levels post treatment hampers residual disease detection. In this study, we analyzed 126 samples collected from 51 patients using a sequential immunohistochemistry (phenotype)/FISH (genotype) approach to detect B-cells with rearrangements of BCR-ABL1 or 11q23/MLL post treatment in 44 and 7 patients, respectively. Cytospin slides, made from residual bone marrow, were stained with a monoclonal CD19 (clone HD37) antibody and scanned on an image analysis system (BioView Duet™) to target the CD19 positive B-cell population. During the scan, the location of each CD19 positive cell was recorded. The slides were subsequently destained and hybridized with FISH probes specific for the genotypic rearrangements mentioned above, with only antibody-targeted cells analyzed (target FISH or T-FISH). Disease was detected by T-FISH and at least one other method in 50 (39.7%) of the 126 samples tested, a finding comparable to the percentage identified by Q-RT-PCR (39.0%) and/or flow cytometry (23.2%). In samples with positive FISH results, T-FISH outperformed or was comparable to standard FISH in detecting disease in 47 (94%) samples. Importantly, T-FISH detected an abnormal cell population in 14/50 (28%) that standard FISH did not detect (p = 0.0064). Eight (57.1%) of these 14 samples had concurrent positive Q-RT-PCR results. The remaining six samples had MLL rearrangements and PCR studies were not performed. In three (6%) samples, abnormal cells were not CD19 positive and thus not detected until a followup area scan of the entire slide revealed low-level positivity in an apparent subset of CD19 negative progenitor B-cells. This latter finding was not observed in the concurrent negative controls. Only two samples (1.6%) with low level BCR-ABL1 positivity by Q-RT-PCR (&gt;10−5) were negative by T-FISH. Serial dilution experiments of CD19-positive/t(9;22)-positive ALL-1 and CD19-negative/t(9;22)-negative Kasumi-1 cell lines demonstrated that T-FISH identified abnormalities at dilutions as low as 10−5, with consistent and reliable detection at 10−3. These observations suggest that antibody-targeted FISH is an effective way to increase the sensitivity of a slide-based assay in detecting residual “high risk” ALL.</jats:p> Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia. Blood
doi_str_mv 10.1182/blood.v110.11.3500.3500
facet_avail Online
Free
finc_class_facet Biologie
Medizin
Chemie und Pharmazie
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEwLjExLjM1MDAuMzUwMA
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEwLjExLjM1MDAuMzUwMA
institution DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
imprint American Society of Hematology, 2007
imprint_str_mv American Society of Hematology, 2007
issn 0006-4971
1528-0020
issn_str_mv 0006-4971
1528-0020
language English
mega_collection American Society of Hematology (CrossRef)
match_str slovak2007antibodytargetedfishanalysisimprovesdetectionofresidualdiseaseinhighriskbcellacutelymphoblasticleukemia
publishDateSort 2007
publisher American Society of Hematology
recordtype ai
record_format ai
series Blood
source_id 49
title Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_unstemmed Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_full Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_fullStr Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_full_unstemmed Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_short Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_sort antibody-targeted fish analysis improves detection of residual disease in “high risk” b-cell acute lymphoblastic leukemia.
topic Cell Biology
Hematology
Immunology
Biochemistry
url http://dx.doi.org/10.1182/blood.v110.11.3500.3500
publishDate 2007
physical 3500-3500
description <jats:title>Abstract</jats:title> <jats:p>A number of prognostically important genetic subtypes of acute lymphoblastic leukemia (ALL) has been identified. Most notably, the presence of t(9;22)/BCR-ABL1 or 11q23/MLL rearrangements in B-cell ALL is a poor prognostic indicator and patients with these subtypes of ALL are candidates for allogeneic stem cell transplantation. Consequently, early detection of minimal residual disease (MRD) is critical for appropriate diagnostic and therapeutic decisions. Current methods for MRD measurements are based on morphologic examinations, flow cytometry, quantitative reverse-transcription polymerase chain reaction (Q-RT-PCR) and cytogenetics/fluorescence in situ hybridization (FISH). While high abnormality rates ease disease detection through standard morphologic and cytogenetic analyses, the presence of cytogenetically-aberrant lymphoblasts at low levels post treatment hampers residual disease detection. In this study, we analyzed 126 samples collected from 51 patients using a sequential immunohistochemistry (phenotype)/FISH (genotype) approach to detect B-cells with rearrangements of BCR-ABL1 or 11q23/MLL post treatment in 44 and 7 patients, respectively. Cytospin slides, made from residual bone marrow, were stained with a monoclonal CD19 (clone HD37) antibody and scanned on an image analysis system (BioView Duet™) to target the CD19 positive B-cell population. During the scan, the location of each CD19 positive cell was recorded. The slides were subsequently destained and hybridized with FISH probes specific for the genotypic rearrangements mentioned above, with only antibody-targeted cells analyzed (target FISH or T-FISH). Disease was detected by T-FISH and at least one other method in 50 (39.7%) of the 126 samples tested, a finding comparable to the percentage identified by Q-RT-PCR (39.0%) and/or flow cytometry (23.2%). In samples with positive FISH results, T-FISH outperformed or was comparable to standard FISH in detecting disease in 47 (94%) samples. Importantly, T-FISH detected an abnormal cell population in 14/50 (28%) that standard FISH did not detect (p = 0.0064). Eight (57.1%) of these 14 samples had concurrent positive Q-RT-PCR results. The remaining six samples had MLL rearrangements and PCR studies were not performed. In three (6%) samples, abnormal cells were not CD19 positive and thus not detected until a followup area scan of the entire slide revealed low-level positivity in an apparent subset of CD19 negative progenitor B-cells. This latter finding was not observed in the concurrent negative controls. Only two samples (1.6%) with low level BCR-ABL1 positivity by Q-RT-PCR (&gt;10−5) were negative by T-FISH. Serial dilution experiments of CD19-positive/t(9;22)-positive ALL-1 and CD19-negative/t(9;22)-negative Kasumi-1 cell lines demonstrated that T-FISH identified abnormalities at dilutions as low as 10−5, with consistent and reliable detection at 10−3. These observations suggest that antibody-targeted FISH is an effective way to increase the sensitivity of a slide-based assay in detecting residual “high risk” ALL.</jats:p>
container_issue 11
container_start_page 3500
container_title Blood
container_volume 110
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792320526195097600
geogr_code not assigned
last_indexed 2024-03-01T10:47:32.246Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Antibody-Targeted+FISH+Analysis+Improves+Detection+of+Residual+Disease+in+%E2%80%9CHigh+Risk%E2%80%9D+B-Cell+Acute+Lymphoblastic+Leukemia.&rft.date=2007-11-16&genre=article&issn=1528-0020&volume=110&issue=11&spage=3500&epage=3500&pages=3500-3500&jtitle=Blood&atitle=Antibody-Targeted+FISH+Analysis+Improves+Detection+of+Residual+Disease+in+%E2%80%9CHigh+Risk%E2%80%9D+B-Cell+Acute+Lymphoblastic+Leukemia.&aulast=Forman&aufirst=Stephen+J.&rft_id=info%3Adoi%2F10.1182%2Fblood.v110.11.3500.3500&rft.language%5B0%5D=eng
SOLR
_version_ 1792320526195097600
author Slovak, Marilyn L., Enriquez, Elmon L., Bedell, Victoria, Kim, Young, Huang, Qin, Smith, David, Stein, Anthony, Forman, Stephen J.
author_facet Slovak, Marilyn L., Enriquez, Elmon L., Bedell, Victoria, Kim, Young, Huang, Qin, Smith, David, Stein, Anthony, Forman, Stephen J., Slovak, Marilyn L., Enriquez, Elmon L., Bedell, Victoria, Kim, Young, Huang, Qin, Smith, David, Stein, Anthony, Forman, Stephen J.
author_sort slovak, marilyn l.
container_issue 11
container_start_page 3500
container_title Blood
container_volume 110
description <jats:title>Abstract</jats:title> <jats:p>A number of prognostically important genetic subtypes of acute lymphoblastic leukemia (ALL) has been identified. Most notably, the presence of t(9;22)/BCR-ABL1 or 11q23/MLL rearrangements in B-cell ALL is a poor prognostic indicator and patients with these subtypes of ALL are candidates for allogeneic stem cell transplantation. Consequently, early detection of minimal residual disease (MRD) is critical for appropriate diagnostic and therapeutic decisions. Current methods for MRD measurements are based on morphologic examinations, flow cytometry, quantitative reverse-transcription polymerase chain reaction (Q-RT-PCR) and cytogenetics/fluorescence in situ hybridization (FISH). While high abnormality rates ease disease detection through standard morphologic and cytogenetic analyses, the presence of cytogenetically-aberrant lymphoblasts at low levels post treatment hampers residual disease detection. In this study, we analyzed 126 samples collected from 51 patients using a sequential immunohistochemistry (phenotype)/FISH (genotype) approach to detect B-cells with rearrangements of BCR-ABL1 or 11q23/MLL post treatment in 44 and 7 patients, respectively. Cytospin slides, made from residual bone marrow, were stained with a monoclonal CD19 (clone HD37) antibody and scanned on an image analysis system (BioView Duet™) to target the CD19 positive B-cell population. During the scan, the location of each CD19 positive cell was recorded. The slides were subsequently destained and hybridized with FISH probes specific for the genotypic rearrangements mentioned above, with only antibody-targeted cells analyzed (target FISH or T-FISH). Disease was detected by T-FISH and at least one other method in 50 (39.7%) of the 126 samples tested, a finding comparable to the percentage identified by Q-RT-PCR (39.0%) and/or flow cytometry (23.2%). In samples with positive FISH results, T-FISH outperformed or was comparable to standard FISH in detecting disease in 47 (94%) samples. Importantly, T-FISH detected an abnormal cell population in 14/50 (28%) that standard FISH did not detect (p = 0.0064). Eight (57.1%) of these 14 samples had concurrent positive Q-RT-PCR results. The remaining six samples had MLL rearrangements and PCR studies were not performed. In three (6%) samples, abnormal cells were not CD19 positive and thus not detected until a followup area scan of the entire slide revealed low-level positivity in an apparent subset of CD19 negative progenitor B-cells. This latter finding was not observed in the concurrent negative controls. Only two samples (1.6%) with low level BCR-ABL1 positivity by Q-RT-PCR (&gt;10−5) were negative by T-FISH. Serial dilution experiments of CD19-positive/t(9;22)-positive ALL-1 and CD19-negative/t(9;22)-negative Kasumi-1 cell lines demonstrated that T-FISH identified abnormalities at dilutions as low as 10−5, with consistent and reliable detection at 10−3. These observations suggest that antibody-targeted FISH is an effective way to increase the sensitivity of a slide-based assay in detecting residual “high risk” ALL.</jats:p>
doi_str_mv 10.1182/blood.v110.11.3500.3500
facet_avail Online, Free
finc_class_facet Biologie, Medizin, Chemie und Pharmazie
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEwLjExLjM1MDAuMzUwMA
imprint American Society of Hematology, 2007
imprint_str_mv American Society of Hematology, 2007
institution DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275
issn 0006-4971, 1528-0020
issn_str_mv 0006-4971, 1528-0020
language English
last_indexed 2024-03-01T10:47:32.246Z
match_str slovak2007antibodytargetedfishanalysisimprovesdetectionofresidualdiseaseinhighriskbcellacutelymphoblasticleukemia
mega_collection American Society of Hematology (CrossRef)
physical 3500-3500
publishDate 2007
publishDateSort 2007
publisher American Society of Hematology
record_format ai
recordtype ai
series Blood
source_id 49
spelling Slovak, Marilyn L. Enriquez, Elmon L. Bedell, Victoria Kim, Young Huang, Qin Smith, David Stein, Anthony Forman, Stephen J. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v110.11.3500.3500 <jats:title>Abstract</jats:title> <jats:p>A number of prognostically important genetic subtypes of acute lymphoblastic leukemia (ALL) has been identified. Most notably, the presence of t(9;22)/BCR-ABL1 or 11q23/MLL rearrangements in B-cell ALL is a poor prognostic indicator and patients with these subtypes of ALL are candidates for allogeneic stem cell transplantation. Consequently, early detection of minimal residual disease (MRD) is critical for appropriate diagnostic and therapeutic decisions. Current methods for MRD measurements are based on morphologic examinations, flow cytometry, quantitative reverse-transcription polymerase chain reaction (Q-RT-PCR) and cytogenetics/fluorescence in situ hybridization (FISH). While high abnormality rates ease disease detection through standard morphologic and cytogenetic analyses, the presence of cytogenetically-aberrant lymphoblasts at low levels post treatment hampers residual disease detection. In this study, we analyzed 126 samples collected from 51 patients using a sequential immunohistochemistry (phenotype)/FISH (genotype) approach to detect B-cells with rearrangements of BCR-ABL1 or 11q23/MLL post treatment in 44 and 7 patients, respectively. Cytospin slides, made from residual bone marrow, were stained with a monoclonal CD19 (clone HD37) antibody and scanned on an image analysis system (BioView Duet™) to target the CD19 positive B-cell population. During the scan, the location of each CD19 positive cell was recorded. The slides were subsequently destained and hybridized with FISH probes specific for the genotypic rearrangements mentioned above, with only antibody-targeted cells analyzed (target FISH or T-FISH). Disease was detected by T-FISH and at least one other method in 50 (39.7%) of the 126 samples tested, a finding comparable to the percentage identified by Q-RT-PCR (39.0%) and/or flow cytometry (23.2%). In samples with positive FISH results, T-FISH outperformed or was comparable to standard FISH in detecting disease in 47 (94%) samples. Importantly, T-FISH detected an abnormal cell population in 14/50 (28%) that standard FISH did not detect (p = 0.0064). Eight (57.1%) of these 14 samples had concurrent positive Q-RT-PCR results. The remaining six samples had MLL rearrangements and PCR studies were not performed. In three (6%) samples, abnormal cells were not CD19 positive and thus not detected until a followup area scan of the entire slide revealed low-level positivity in an apparent subset of CD19 negative progenitor B-cells. This latter finding was not observed in the concurrent negative controls. Only two samples (1.6%) with low level BCR-ABL1 positivity by Q-RT-PCR (&gt;10−5) were negative by T-FISH. Serial dilution experiments of CD19-positive/t(9;22)-positive ALL-1 and CD19-negative/t(9;22)-negative Kasumi-1 cell lines demonstrated that T-FISH identified abnormalities at dilutions as low as 10−5, with consistent and reliable detection at 10−3. These observations suggest that antibody-targeted FISH is an effective way to increase the sensitivity of a slide-based assay in detecting residual “high risk” ALL.</jats:p> Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia. Blood
spellingShingle Slovak, Marilyn L., Enriquez, Elmon L., Bedell, Victoria, Kim, Young, Huang, Qin, Smith, David, Stein, Anthony, Forman, Stephen J., Blood, Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia., Cell Biology, Hematology, Immunology, Biochemistry
title Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_full Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_fullStr Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_full_unstemmed Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_short Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
title_sort antibody-targeted fish analysis improves detection of residual disease in “high risk” b-cell acute lymphoblastic leukemia.
title_unstemmed Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in “High Risk” B-Cell Acute Lymphoblastic Leukemia.
topic Cell Biology, Hematology, Immunology, Biochemistry
url http://dx.doi.org/10.1182/blood.v110.11.3500.3500